EFTR

eFFECTOR Therapeutics, Inc.

1.29 USD
+0.01 (+0.78%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

eFFECTOR Therapeutics, Inc. stock is down -34.85% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May.

About eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E)